Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles, Martin Barrett, Robin Foà, et al.
Advances in Therapy (2017) Vol. 34, Iss. 10, pp. 2232-2273
Open Access | Times Cited: 507

Showing 1-25 of 507 citing articles:

The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
Gabriela Mladonická Pavlasová, Marek Mráz
Haematologica (2020) Vol. 105, Iss. 6, pp. 1494-1506
Open Access | Times Cited: 292
Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
Thomas Hueso, Cécile Pouderoux, Hélène Péré, et al.
Blood (2020) Vol. 136, Iss. 20, pp. 2290-2295
Open Access | Times Cited: 283
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Qian Ding, Wei Hu, Ran Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 203
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire
Sebastian P. Haen, Markus Löffler, Hans‐Georg Rammensee, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 10, pp. 595-610
Open Access | Times Cited: 172
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Li-Chung Tsao, Jeremy Force, Zachary C. Hartman
Cancer Research (2021) Vol. 81, Iss. 18, pp. 4641-4651
Open Access | Times Cited: 142
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Matthew J. Matasar, Marcelo Capra, Muhi̇t Özcan, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 5, pp. 678-689
Closed Access | Times Cited: 115
Anticancer Drugs: Recent Strategies to Improve Stability Profile, Pharmacokinetic and Pharmacodynamic Properties
Giuseppina Ioele, Martina Chieffallo, Maria Antonietta Occhiuzzi, et al.
Molecules (2022) Vol. 27, Iss. 17, pp. 5436-5436
Open Access | Times Cited: 114
Designing Cancer Immunotherapies That Engage T Cells and NK Cells
Oleksandr Kyrysyuk, Kai W. Wucherpfennig
Annual Review of Immunology (2022) Vol. 41, Iss. 1, pp. 17-38
Open Access | Times Cited: 107
Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy
Gian Marco Leone, Katia Mangano, Maria Cristina Petralia, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1630-1630
Open Access | Times Cited: 77
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 53
Flt3- and Tie2-Cre tracing identifies regeneration in sepsis from multipotent progenitors but not hematopoietic stem cells
Ann-Kathrin Fanti, Katrin Busch, Alessandro Greco, et al.
Cell stem cell (2023) Vol. 30, Iss. 2, pp. 207-218.e7
Open Access | Times Cited: 43
Emerging roles of Aurora-A kinase in cancer therapy resistance
Dayong Zheng, Jun Li, Han Yan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 7, pp. 2826-2843
Open Access | Times Cited: 43
An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis
Ibrahim M Dighriri, Ahood A Aldalbahi, Fatimah Albeladi, et al.
Cureus (2023)
Open Access | Times Cited: 42
A tale of two antibodies: obinutuzumab versus rituximab
Ciara L. Freeman, Laurie H. Sehn
British Journal of Haematology (2018) Vol. 182, Iss. 1, pp. 29-45
Open Access | Times Cited: 154
B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis—Role in Pathogenesis and Effect of Immunosuppressive Treatments
Desmond Y. H. Yap, Tak Mao Chan
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 24, pp. 6231-6231
Open Access | Times Cited: 138
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
Dionysos Slaga, Diego Ellerman, T. Noelle Lombana, et al.
Science Translational Medicine (2018) Vol. 10, Iss. 463
Closed Access | Times Cited: 116
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Ana Bela Sarmento‐Ribeiro, Andreas Scorilas, Ana Cristina Gonçalves, et al.
Drug Resistance Updates (2019) Vol. 47, pp. 100646-100646
Closed Access | Times Cited: 112
The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell–mediated resistance to metastasis
Irene Mattiola, Federica Tomay, Maria De Pizzol, et al.
Nature Immunology (2019) Vol. 20, Iss. 8, pp. 1012-1022
Open Access | Times Cited: 111
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Vanessa Buatois, Zoë Johnson, Susana Salgado-Pires, et al.
Molecular Cancer Therapeutics (2018) Vol. 17, Iss. 8, pp. 1739-1751
Open Access | Times Cited: 103
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies
Dimitris Skokos, Janelle Waite, Lauric Haber, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 525
Open Access | Times Cited: 98
Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies
Mimmi L. E. Lundahl, Silvia Fogli, Paula E. Colavita, et al.
RSC Chemical Biology (2021) Vol. 2, Iss. 4, pp. 1004-1020
Open Access | Times Cited: 96
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
Vincenzo Marasco, Cristiana Carniti, Anna Guidetti, et al.
British Journal of Haematology (2021) Vol. 196, Iss. 3, pp. 548-558
Open Access | Times Cited: 90
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil, et al.
Blood (2019) Vol. 134, Iss. 21, pp. 1811-1820
Open Access | Times Cited: 81
Overcoming the challenges associated with CD3+ T-cell redirection in cancer
Ajit Kumar Singh, Sundee Dees, Iqbal S. Grewal
British Journal of Cancer (2021) Vol. 124, Iss. 6, pp. 1037-1048
Open Access | Times Cited: 80
Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults
Casey L. McAtee, Joseph Lubega, Kristen Underbrink, et al.
JAMA Network Open (2021) Vol. 4, Iss. 2, pp. e2036321-e2036321
Open Access | Times Cited: 64
Page 1 - Next Page

Scroll to top